CGI approves Mitsui's 26% stake buy in Arch Pharmalabs

摘要

The Competition Commission of India (CCI) has approved Japanese firm Mitsui's proposed takeover of 26.71 per cent stake in domestic biopharmaceuti-cal firm, Arch Pharmalabs - making it the first pharma sector deal cleared by the fair trade regulator. CCI said the proposed acquisition of further 26.71 per cent stake by Mitsui in Arch "is not likely to create any adverse competition concern". Once the deal is complete, Mitsui's total stake in biopharmaceuti-cal firm will increase to 31.96 per cent, from its existing holding of 5.25 per cent. Arch is engaged in the business of manufacture and sale of active pharmaceutical ingredients (APIs).